等待开盘 08-15 09:30:00 美东时间
-1.380
-5.29%
Across the recent three months, 4 analysts have shared their insights on Pennan...
今天 05:00
Wells Fargo analyst Stephen Baxter maintains Pennant Gr (NASDAQ:PNTG) with a Equal-Weight and lowers the price target from $31 to $29.
08-14 21:48
Pennant Group shares are trading higher after the company reported better-than-...
08-07 21:45
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
The Pennant Group, Inc. announced it will release its second quarter 2025 financial results on August 6, 2025, and host a live webcast on August 7, 2025, at 10:00 a.m. Mountain Time (12:00 p.m. Eastern Time). Investors can access the webcast or related financial information at http://investor.pennantgroup.com, which will be available for replay until August 6, 2026. The company provides home health, hospice, and senior living services through its...
07-22 23:05
Pennant Gr (NASDAQ:PNTG) has been analyzed by 4 analysts in the last three mont...
07-17 02:00
Truist Securities analyst David Macdonald maintains Pennant Gr (NASDAQ:PNTG) with a Hold and lowers the price target from $32 to $28.
07-16 22:27
A Raymond James analyst is warning that a just proposed 6.4% cut in Medicare payments to home health care agencies in 2026 introduced by the Trump administration could be a "death knell" for UnitedHea...
07-01 23:17
The Pennant Group has acquired GrandCare Health Services, renaming it GrandCare Home Health. The purchase expands Pennant's home health services in Southern California, including Los Angeles, Orange, Riverside, and San Diego counties. Pennant CEO Brent Guerisoli emphasized the strategic importance of this move, as it enhances their presence in a region where they already have a strong senior living network. GrandCare is known for its high-quality...
07-01 20:44
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139478829918380033.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim:维持Metsera(MTSR)"买入"评级,目标价从56美元升至62美元</p> <p>• 摩根大通:维持Avidity Biosciences(RNA)"超配"评级,目标价从57美元升至59美元</
06-11 09:43